Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations

Author： Park In   Kim Jin   Jung Jae   Han Ji-Youn  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.28, Iss.6, 2010-12, pp. : 791-799

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Across the Universe of K-Ras Mutations in Non-Small-Cell-Lung Cancer

By  

Current Pharmaceutical Design, Vol. 20, Iss. 24, 2014-05 ,pp. : 3933-3943

Bentham Science Publishers

Access to resources Recommend Favorite

Gefitinib in non-small cell lung cancer

By Tamura Kenji   Fukuoka Masahiro  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 6, 2005-06 ,pp. : 985-993

Informa Healthcare

Access to resources Recommend Favorite

The role of gefitinib in the management of Asian patients with non-small cell lung cancer

By Chang Alex Y  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 3, 2008-03 ,pp. : 401-411

Informa Healthcare

Access to resources Recommend Favorite

Spotlight on Gefitinib in Non-Small-Cell Lung Cancer

By Frampton James E.   Easthope Stephanie E.  

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 133-136

Adis International

Access to resources Recommend Favorite

Gefitinib is an effective treatment for patients with non-small-cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor

By  

Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite